ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Chronische lymfatische leukemie (CLL) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Chronische lymfatische leukemie / kleincellig lymfocytair lymfoom' van de HOVON CLL werkgroep.

Literatuur

  1. Eichhorst et al. ESMO guidelines Committee. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; sept; 26 suppl 5: v78-v84
  2. Dreger P et al. Managing high risk CLL during transition to a new treatment era: stem cell transplantation or novel agents. Blood 2014 dec 18;124(26):3841
  3. Stephens DM and Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019; 133(12):1298-1307
  4. Böttcher et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analyses from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30(9):980-988
  5. Wierda et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021; 35:3059-3072
  6. Te Raa DG et al. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group, Leukemia & Lymphoma 2022, DOI: 10.1080/10428194.2022.2084731 

 

Ga terug naar de CLL homepage of lees meer over CLL:

Ga terug naar de algemene homepage Behandelprotocollen.